Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Easy to Deliver and Patient Friendly

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Dec 13, 2020 6:43pm

228 Views

Post# 32096673

RE:RE:RE:Easy to Deliver and Patient Friendly

Roger Dumoulin-White wrote this in the April 2014 Cantech Letter:

"Annual sales would ramp immediately after commercialization, but assuming a treatment cost of $50,000 per patient with 1000 patients treated annually at each of 50 facilities, gross revenue from the procedures would total $2.5-billion. If Theralase was paid 50% of the gross revenue for the PDC and the laser system used to activate it, the Company’s gross revenues after a two to three year ramp could potentially be $1.25-billion per year."

newdaydawning wrote: My recollection from an earlier post is somewhere in the range of US$50K.

Longholder99 wrote: Any thougts on what Theralase will charge for the NMIBC treatment?